NSRX NSRX
Company Profile ↓Company Overview
NSRX (NSRX) is a publicly traded company listed on with a market capitalization of $29.93M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -59.76% |
| 6 Months: | -46.19% |
| 3 Months: | +15.28% |
| 1 Month: | +8.85% |
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)55.60 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 63.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 2.04M | 1.15M | 1.08M | 4.90M |
| Operating Income | -2.04M | -1.15M | -1.08M | -4.90M |
| EBITDA | -2.13M | -1.15M | -1.08M | -4.90M |
| Interest Expense | 18.00K | 49.00K | 29.00K | - |
| Pretax Income | -2.15M | -1.00M | -1.55M | -5.80M |
| Tax Provision | - | - | - | - |
| Net Income | -1.71M | -1.05M | -1.53M | -5.86M |
| Diluted EPS | -0.24 | -0.20 | -0.22 | -0.72 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 417.00K | 444.00K | 717.00K | 5.00M |
| Current Assets | 417.00K | 444.00K | 457.00K | 4.86M |
| Cash & Equivalents | 154.00K | 193.00K | 284.00K | 1.24M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 3.20M | 4.24M | 3.93M | 2.24M |
| Current Liabilities | 3.20M | 4.24M | 3.93M | 2.16M |
| Long Term Debt | - | - | - | - |
| Total Debt | 1.57M | 2.46M | 1.80M | 118.00K |
| Total Equity | -2.79M | -3.80M | -3.21M | 2.77M |
| Shares Outstanding | 9.06M | 9.06M | 9.06M | 9.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -1.21M | -1.03M | -665.00K | -4.92M |
| Investing Cash Flow | -160.00K | 0 | 0 | -3.01M |
| Financing Cash Flow | 1.24M | 1.05M | 770.00K | 8.92M |
| Capital Expenditure | - | - | - | -14.00K |
| Free Cash Flow | -1.21M | -1.03M | -665.00K | -4.93M |
| Net Change in Cash | -133.00K | 26.00K | 105.00K | 988.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 61.4% | 27.7% | 47.7% | -211.6% |
| ROCE % | 73.3% | 30.2% | 33.6% | -172.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NSRX
Nasus Pharma (NSRX) Stock Forecast and Price Target 2026 - MarketBeat
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE05QUdYOFJBdGJrLWQ3ek9HN3J0a1ExSnl6TUR3Qzkzc1RZUDhlWDVyNnhWT0tPVm5vZXpsNEIwVnVnVmd6QU4weE0zQ0ZlSmJVbm5ic1lJNTNDR3c0c0tjMXRRc1NjZmlWV3FGQ3B3?oc=5" target="_blank">Nasus Pharma (NSRX)…
A new CEO takes charge as Nasus Pharma advances nasal anaphylaxis treatment - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPTk1TbUZnNTdNdnlKTkUybnlBblVicVpINHNKR3BXODM0dE1LSW1HRF9fRmxiczZhSXAxTFJ0Y0J5R2t1b3k0MnZ1YWxtOGZrR21JY0h2TktNMlVrTzlwQ1hvS3BLZmFCYTlydGFVRU1BM3N4RGc1WUdWLWJwU2huN2VjYW10VklxUElXbG…
Insider Purchase: Chief Executive Officer of $NSRX Buys 2,900 Shares | NSRX Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxORjRRVFpUZ2xhLTUwN2d1ajlVaGFDTzBwTFlmOW9DdmN6cWs0SFJwMmNTbE5SNkxHVnRSdHRFd2NLRmlET2NMdnhubEE1OC0xUkQyMXR2S1BaTjNRV0VzWnRIdXZ1RWh1Qy1pNmdlbDh5WlFjYXZtUXAydk5SWFN4VENLblFqeTcwcDVOX2…
NSRX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9FMHRPalp1YVl0UDFYYU1VSlJTX25kY1JHS1B6TzhBYkF3SFRYeWZaREFEU2RVWlY4QXY1LVk4SXU4UXBWai1ROWpVelFaMjN3UWcxcjNDN0M2OWhicnFmNXZNdGZKcy1kZ001UHRQMmVUNmJmMjBJ?oc=5" target="_blank">NSRX Fo…
Nasus Pharma Ltd (NSRX) Income Statement - TradingKey
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE5XTHVJUlctcmpmZk9zMzRrbXFSeEhORXVZOHVBNUpHNkNUeHEtM2dpdTVwV3BIdHhXRmJ1LVNaSjhWMmU5bjVpRUctNU1nbWg5VnI2M3VZQ2NTQXZockY0eUxvSEFXT0E2YTdWbWthc1M?oc=5" target="_blank">Nasus Pharma Ltd…
Nasus Pharma (NSRX) CEO Dan Teleman resigns as CEO and director - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNQ2xtVEpKeWFQYXh4VTVMZHA4VHpRX0VTamY5X0dLQi1IS3U0SnlXanNfVkRrMzMxNkNvSHlWMzFUQThSaFZSdnBYeWF6T25pczk4YWFsazJjaTh2d3hJNUpqUm5KM0l2SXkySVY2MHN6WHhBeFdfVzlqY2tHdzZYV3lUMm5URU1kSjJHaE…
NSRX — Frequently Asked Questions
What is the current share price of NSRX?
As of 2026-08-05 17:25 PDT, NSRX trades at $3.32 on NASDAQ/NYSE. Its 52-week range is $2.01 to $9.15.
What is the market capitalisation of NSRX?
NSRX has a market capitalisation of $29.93M on NASDAQ/NYSE.
What is the P/E ratio of NSRX?
NSRX trades at a trailing price-to-earnings (P/E) ratio of -4.61. Its price-to-book (P/B) ratio is 10.81.
Is NSRX a good stock to buy?
This page provides a data-driven analysis of NSRX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.